activeingredient
adversereaction
auc
chemoclass
clearance
cmax
co-administereddrug
company
corecomposition
dose
duration
eliminationhalflife
fdaapprovaldate
frequency
inactiveingredient
indication
molecularweight
nanoparticle
particlediameter
plasmahalflife
pre-existingdisease
routeofadministration
surfacecharge
surfacecoating
tmax
tradename
u.s.patent
volumeofdistribution